Combined magnetic resonance spectroscopy and dynamic contrast-enhanced imaging for prostate cancer detection

Urologic Oncology: Seminars and Original Investigations

Volumn 31, Issue 6, 2013, Pages 761-765

  Perdonà, Sisto ^a   Di Lorenzo, Giuseppe ^b   Autorino, Riccardo ^c   Buonerba, Carlo ^b   De Sio, Marco ^c   Setola, Sergio Venanzio ^a   Fusco, Roberta ^a   Ronza, Francesco Michele ^c   Caraglia, Michele ^c   Ferro, Matteo ^b   Petrillo, Antonella ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BIOCHEMICAL MARKER; CHOLINE; CITRIC ACID; DUTASTERIDE; FINASTERIDE; GADOTERATE MEGLUMINE; GADOTERIC ACID; LIPID; PROSTATE SPECIFIC ANTIGEN; WATER;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; COHORT ANALYSIS; CONTRAST ENHANCEMENT; DIAGNOSTIC TEST ACCURACY STUDY; DYNAMIC CONTRAST ENHANCED MAGNETIC RESONANCE IMAGING; ELECTRON SPIN RESONANCE; GLEASON SCORE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE VOLUME; REPEAT PROCEDURE; SENSITIVITY AND SPECIFICITY; TRANSRECTAL ULTRASONOGRAPHY;

MAGNETIC RESONANCE; PROSTATE CANCER; SPECTROSCOPY;

AGED; BIOPSY; COHORT STUDIES; CONTRAST MEDIA; HUMANS; IMAGING, THREE-DIMENSIONAL; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MEGLUMINE; MIDDLE AGED; MULTIMODAL IMAGING; NEOPLASM GRADING; ORGANOMETALLIC COMPOUNDS; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 84880697728     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2011.07.010     Document Type: Article

References (14)

1. Kawachi M.H., Bahnson R.R., Barry M., et al. NCCN clinical practice guidelines in oncology: Prostate cancer early detection. J Natl Compr Cancer Network 2010, 8: 240-262.
2. Thompson I.M., Pauler D.K., Goodman P.J., et al. Prevalence of prostate cancer among men with a prostate-specific antigen level less or equal to 4.0 ng per milliliter. N Engl J Med 2004, 350: 2239-2246.
3. Perdonà S., Cavadas V., Di Lorenzo G., et al. Prostate cancer detection in the "grey area" of prostate-specific antigen below 10 ng/ml: Head-to-head comparison of the updated PCPT calculator and Chun's nomogram, two risk estimators incorporating prostate cancer antigen 3. Eur Urol 2011, 59: 81-87.
4. Presti J.C. Repeat prostate biopsy-when, where, and how. Urol Oncol 2009, 27: 312-314.
5. Eichler K., Hempel S., Wilby J., et al. Diagnostic value of systematic biopsy methods in the investigation of prostate cancer: A systematic review. J Urol 2006, 175: 1605-1612.
6. Umbehr M., Bachmann L.M., Held U., et al. Combined magnetic resonance imaging and magnetic resonance spectroscopy imaging in the diagnosis of prostate cancer: A systematic review and meta-analysis. Eur Urol 2009, 55: 575-590.
7. Pondman K.M., Fütterer J.J., ten Haken B., et al. MR-guided biopsy of the prostate: An overview of techniques and a systematic review. Eur Urol 2008, 54: 517-527.
8. Sciarra A., Panebianco V., Salciccia S., et al. Modern role of magnetic resonance and spectroscopy in the imaging of prostate cancer. Urol Oncol 2011, 29: 12-20.
9. Carlani M., Mancino S., Bonanno E., et al. Combined morphological, [1H]-MR spectroscopic and contrast-enhanced imaging of human prostate cancer with a 3-Tesla scanner: Preliminary experience. Radiol Med 2008, 113: 670-688.
10. 3) spatial resolution. Radiology 1996, 198: 795-805.
11. Delongchamps N.B., Rouanne M., Flam T., et al. Multiparametric magnetic resonance imaging for the detection and localization of prostate cancer: Combination of T2-weighted, dynamic contrast-enhanced and diffusion-weighted imaging. BJU Int 2011, 107: 1411-1418.
12. Sciarra A., Panebianco V., Ciccariello M., et al. Value of magnetic resonance spectroscopy imaging and dynamic contrast-enhanced imaging for detecting prostate cancer foci in men with prior negative biopsy. Clin Cancer Res 2010, 16: 1875-1883.
13. Beyersdorff D., Taupitz M., Winkelmann B., et al. Patients with a history of elevated prostate-specific antigen levels and negative transrectal US-guided quadrant or sextant biopsy results: Value of MR imaging. Radiology 2002, 224: 701-706.
14. Kozlowski P., Chang S.D., Jones E.C., et al. Combined diffusion-weighted and dynamic contrast-enhanced MRI for prostate cancer diagnosis-correlation with biopsy and histopathology. J Magn Reson Imaging 2006, 24: 108-113.